Discovery of novel dual adenosine A1/A2A receptor antagonists using deep learning, pharmacophore modeling and molecular docking.

Adenosine receptors (ARs) have been demonstrated to be potential therapeutic targets against Parkinson's disease (PD). In the present study, we describe a multistage virtual screening approach that identifies dual adenosine A1 and A2A receptor antagonists using deep learning, pharmacophore mode...

Full description

Saved in:
Bibliographic Details
Main Authors: Mukuo Wang, Shujing Hou, Yu Wei, Dongmei Li, Jianping Lin
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-03-01
Series:PLoS Computational Biology
Online Access:https://journals.plos.org/ploscompbiol/article/file?id=10.1371/journal.pcbi.1008821&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850240042291691520
author Mukuo Wang
Shujing Hou
Yu Wei
Dongmei Li
Jianping Lin
author_facet Mukuo Wang
Shujing Hou
Yu Wei
Dongmei Li
Jianping Lin
author_sort Mukuo Wang
collection DOAJ
description Adenosine receptors (ARs) have been demonstrated to be potential therapeutic targets against Parkinson's disease (PD). In the present study, we describe a multistage virtual screening approach that identifies dual adenosine A1 and A2A receptor antagonists using deep learning, pharmacophore models, and molecular docking methods. Nineteen hits from the ChemDiv library containing 1,178,506 compounds were selected and further tested by in vitro assays (cAMP functional assay and radioligand binding assay); of these hits, two compounds (C8 and C9) with 1,2,4-triazole scaffolds possessing the most potent binding affinity and antagonistic activity for A1/A2A ARs at the nanomolar level (pKi of 7.16-7.49 and pIC50 of 6.31-6.78) were identified. Further molecular dynamics (MD) simulations suggested similarly strong binding interactions of the complexes between the A1/A2A ARs and two compounds (C8 and C9). Notably, the 1,2,4-triazole derivatives (compounds C8 and C9) were identified as the most potent dual A1/A2A AR antagonists in our study and could serve as a basis for further development. The effective multistage screening approach developed in this study can be utilized to identify potent ligands for other drug targets.
format Article
id doaj-art-ef473c165dcd4f50be7bb52ffec0279f
institution OA Journals
issn 1553-734X
1553-7358
language English
publishDate 2021-03-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS Computational Biology
spelling doaj-art-ef473c165dcd4f50be7bb52ffec0279f2025-08-20T02:00:59ZengPublic Library of Science (PLoS)PLoS Computational Biology1553-734X1553-73582021-03-01173e100882110.1371/journal.pcbi.1008821Discovery of novel dual adenosine A1/A2A receptor antagonists using deep learning, pharmacophore modeling and molecular docking.Mukuo WangShujing HouYu WeiDongmei LiJianping LinAdenosine receptors (ARs) have been demonstrated to be potential therapeutic targets against Parkinson's disease (PD). In the present study, we describe a multistage virtual screening approach that identifies dual adenosine A1 and A2A receptor antagonists using deep learning, pharmacophore models, and molecular docking methods. Nineteen hits from the ChemDiv library containing 1,178,506 compounds were selected and further tested by in vitro assays (cAMP functional assay and radioligand binding assay); of these hits, two compounds (C8 and C9) with 1,2,4-triazole scaffolds possessing the most potent binding affinity and antagonistic activity for A1/A2A ARs at the nanomolar level (pKi of 7.16-7.49 and pIC50 of 6.31-6.78) were identified. Further molecular dynamics (MD) simulations suggested similarly strong binding interactions of the complexes between the A1/A2A ARs and two compounds (C8 and C9). Notably, the 1,2,4-triazole derivatives (compounds C8 and C9) were identified as the most potent dual A1/A2A AR antagonists in our study and could serve as a basis for further development. The effective multistage screening approach developed in this study can be utilized to identify potent ligands for other drug targets.https://journals.plos.org/ploscompbiol/article/file?id=10.1371/journal.pcbi.1008821&type=printable
spellingShingle Mukuo Wang
Shujing Hou
Yu Wei
Dongmei Li
Jianping Lin
Discovery of novel dual adenosine A1/A2A receptor antagonists using deep learning, pharmacophore modeling and molecular docking.
PLoS Computational Biology
title Discovery of novel dual adenosine A1/A2A receptor antagonists using deep learning, pharmacophore modeling and molecular docking.
title_full Discovery of novel dual adenosine A1/A2A receptor antagonists using deep learning, pharmacophore modeling and molecular docking.
title_fullStr Discovery of novel dual adenosine A1/A2A receptor antagonists using deep learning, pharmacophore modeling and molecular docking.
title_full_unstemmed Discovery of novel dual adenosine A1/A2A receptor antagonists using deep learning, pharmacophore modeling and molecular docking.
title_short Discovery of novel dual adenosine A1/A2A receptor antagonists using deep learning, pharmacophore modeling and molecular docking.
title_sort discovery of novel dual adenosine a1 a2a receptor antagonists using deep learning pharmacophore modeling and molecular docking
url https://journals.plos.org/ploscompbiol/article/file?id=10.1371/journal.pcbi.1008821&type=printable
work_keys_str_mv AT mukuowang discoveryofnoveldualadenosinea1a2areceptorantagonistsusingdeeplearningpharmacophoremodelingandmoleculardocking
AT shujinghou discoveryofnoveldualadenosinea1a2areceptorantagonistsusingdeeplearningpharmacophoremodelingandmoleculardocking
AT yuwei discoveryofnoveldualadenosinea1a2areceptorantagonistsusingdeeplearningpharmacophoremodelingandmoleculardocking
AT dongmeili discoveryofnoveldualadenosinea1a2areceptorantagonistsusingdeeplearningpharmacophoremodelingandmoleculardocking
AT jianpinglin discoveryofnoveldualadenosinea1a2areceptorantagonistsusingdeeplearningpharmacophoremodelingandmoleculardocking